Invivyd expects to advance VBY329 toward IND readiness in 2H 2026 for development in pediatric RSV prophylaxis, a blockbuster pharmaceutical market in 2024, expected to grow to $3-$4 billion in annual ...

“Our QUELIMMUNE net revenue in the first quarter was $495,000, a solid increase of 69% from the first quarter of last year,” said (Senior Vice President of Commercial & Business Operations Tim Varacek ...

Berkshire Hathaway enters the Greg Abel era as valuation refocuses on P/B ratio, insurance earnings, and a record $397B cash ...

First Boric Acid Offtake Agreement -- 7,500 tons per year signed with a domestic and industrial boric acid end user, ...

PolyPid Ltd. (NASDAQ: PYPD) Q1 2026 Earnings Call Transcript May 13, 2026 PolyPid Ltd. beats earnings expectations. Reported ...

Pro forma gross profit for the quarter was $15 million, yielding a pro forma gross margin of 62.9% compared to 68.0% for fiscal Q1 ended March 31, 2025, with the difference primarily related to tissue ...

The rise of special purpose acquisition companies (SPACs) has led to a surge in shareholder litigation, particularly in the Delaware Court ...

Good day ladies and gentlemen and welcome to The Compass Pathways 1st Quarter Results Conference call. At this time, all participants are in listen only mode. As a reminder, this call is being ...

Q1 2026 Management View CEO Kabir Nath said the quarter was “validated by the confirmation of a rolling NDA submission and review and the award of a Commissioner's National Priority Voucher or CNPV,” ...